




Integrazione dei principi FAIR nel processo di ricerca biomedica: la creazione del Registro Regionale della Regione Sardegna

Alessandro Sulis

CRS4 – Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna




Riuso dei dati nella ricerca: disponibilità



Fonte: *The Availability of Research Data Declines Rapidly with Article Age*, Vines et al., *Curr Biol.* 2014 Jan 6;24(1):94-97

Riuso dei dati nella ricerca: riproducibilità



Fonte: Freedman LP, Cockburn IM, Simcoe TS (2015) The Economics of Reproducibility in Preclinical Research. PLoS Biol 13(6): e1002165

Cosa è successo di recente



PERSPECTIVE
Ensuring Choice for People with Kidney Failure — Dialysis, Supportive Care, and ...

Get your copy of this valuable eBook today →

POINTS OF VIEW
Why I Stay — The Other Side of Underrepresentation in Academia

ORIGINAL ARTICLE
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

ORIGINAL ARTICLE
A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries

EDITORIAL
The Beginning of Genomic Therapies for ALS

Editor's Note: This editorial was published on June 2, 2020, at NEJM.org.

EDITORIAL
Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.


Eric J. Rubin, M.D., Ph.D.

Article Metrics
3 References 1 Citing Article

June 18, 2020
N Engl J Med 2020; 382:2464
DOI: 10.1056/NEJM2020822

Related Articles

ORIGINAL ARTICLE JUN 18, 2020



ARTICLES | ONLINE FIRST

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Prof Mandeep R Mehra, MD, Sapan S Desai, MD, Prof Frank Ruschitzka, MD, Amit N Patel, MD

Published: May 22, 2020 DOI: https://doi.org/10.1016/S0140-6736(20)31180-4 Check for updates

Summary

Background

Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.

Methods

We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or

PDF [1 MB] Figures Save Share Reprints Request

Recommend this journal to your librarian

ADVERTISEMENT

Feedback

Paper in un primo momento accettato e successivamente ritrattato in seguito alla mancata disponibilità dei dati per la verifica dei risultati

Parola chiave: FAIR



«If a game competition is fair, it is done according to the rules»

«If something is fair, it is reasonable and is what you expect or deserve»

SCIENTIFIC DATA



Amended: Addendum

Comment: The FAIR Guiding Principles for scientific data management and stewardship

Mark D. Wilkinson *et al.*^a

Received: 10 December 2015
Accepted: 12 February 2016
Published: 15 March 2016

OPEN

SUBJECT CATEGORIES
» Research data
» Publication characteristics

There is an urgent need to improve the infrastructure supporting the reuse of scholarly data. A diverse set of stakeholders—representing academia, industry, funding agencies, and scholarly publishers—have come together to design and jointly endorse a concise and measurable set of principles that we refer to as the FAIR Data Principles. The intent is that these may act as a guideline for those wishing to enhance the reusability of their data holdings. Distinct from peer initiatives that focus on the human scholar, the FAIR Principles put specific emphasis on enhancing the ability of machines to automatically find and use the data, in addition to supporting its reuse by individuals. This Comment is the first formal publication of the FAIR Principles, and includes the rationale behind them, and some exemplar implementations in the community.

Supporting discovery through good data management
Good data management is not a goal in itself, but rather is the key conduit leading to knowledge

Che cosa ci aspettiamo dal concetto «fair» applicato ai cosiddetti «*research objects*»?

Sia gli umani sia le macchine possono «giocare» con i risultati

Machine Actionability

Findable



Created by Zenzeta Icons Design
from Noun Project

Dati e metadati devono avere un identificativo univoco e persistente

I dati devono essere descritti da un insieme di metadati sufficientemente ampio

I metadati devono includere in maniera esplicita l'ID dei dati ai quali sono riferiti




Created by monkik
from Noun Project

Accessible


Dati e metadati accessibili tramite il loro ID univoco e protocolli aperti

I metadati devono essere sempre accessibili, anche qualora i dati non fossero più disponibili

Attenzione: FAIR data non significa open data!
as open as possible, as closed as necessary



Interoperable




Created by priyanka
from Noun Project

Dati e metadati utilizzano un linguaggio standard per la rappresentazione dei concetti

Dati e metadati utilizzano nomenclatori che rispettano essi stessi i principi FAIR

Dati e metadati utilizzano riferimenti ad altri dati e metadati



Created by Vectors Market
from Noun Project


Reusable

Dati e metadati descritti da un numero di attributi sufficientemente ampio


Dati e metadati associati alle loro informazioni di *provenance*

Dati e metadati utilizzano vocabolari e nomenclatori noti all'interno del dominio

Il programma IFAIR e il Registro per la Ricerca Biomedica della Regione Sardegna



Il processo di FAIR-ificazione



Altre parole chiave: modello semantico e ontologia

MODELLO SEMANTICO

Un modello in cui sia i (meta) dati sia le loro valorizzazioni sono univocamente definiti tramite ontologie

ONTOLOGIA

Formalizzazione dei concetti e delle relazioni tra di essi all'interno di uno specifico dominio
(es. clinico/biomedico)

Patologia	Area Terapeutica
Epilessia	Neurologia

Patologia → DCAT → <https://www.w3.org/ns/dcat#theme>

Epilessia → MESH → <http://purl.bioontology.org/ontology/MESH/D004827>

who is the manager of the team who won champions league in 2010

X | | 🔍

Tutti Notizie Immagini Video Shopping Altro Impostazioni Strumenti

Circa 131.000.000 risultati (1,02 secondi)




Suggerimento: Cerca risultati solo in Italiano. Puoi specificare la lingua di ricerca in Preferenze.

José Mourinho

José Mourinho revealed after the match that he would likely resign from Inter to pursue the goal of being the first manager to win the Champions League with three clubs.



Implementazione del registro: architettura



Implementazione del registro: machine actionability

Sardinian Registry of Biomedical Research

This is the Sardinian Registry of Biomedical Research. Here researchers can get information about biomedical studies being conducted in the region of Sardinia

Back

FOO BAR TITLE

Institution	Ethic Committee
Experimentation Center	Sacred Hearth Ethic Committee
Deparment of General Surgery	
Hospital	Sacred Heart
Start Date	

2019-10-11
Status
Planned

Contacts

Principal Investigator
Chris Turk
<input checked="" type="checkbox"/>
Data Steward

[Download Study Documents](#)

Details

Gallbladder coalcolosis is present in approximately 10-15% of the adult adult population in Western countries. The gold standard in the management of symptomatic cholelithiasis is laparoscopic cholecystectomy. laparoscopic cholecystectomy. Nowadays, the technique surgical... technique of laparoscopic cholecystectomy has become widespread and standardised. In recent years, the organisational model (or care setting) has evolved. the organisational model (or care setting) has evolved. which has now mostly changed from ordinary hospitalisation to one-day

+

Disease Cholelithiasis

Therapeutic Area Liver Diseases, Cholestasis, Intrahepatic

Cohort Size 300

Collected Data Type Sample from organism, Medical Record, Physiological Measurement Data, Survey data

Collected Specimen Type Serum, Whole blood, Plasma, Tissue

```
<http://purl.org/srbr/fdp/dataset/foobar> a dcat:Dataset, dcat:Resource;
dct:title "Foo Bar Title";
rdfs:label "Foo Bar Title", "FOO BAR";
dct:hasVersion "0.1";
dct:publisher orcid:0000-xxxx-yyyy-zzzz;
dct:description """Gallbladder coalcolosis is present in approximately 10-15% of the adult adult population in Western countries. The gold standard in the management of symptomatic cholelithiasis is laparoscopic cholecystectomy. laparoscopic cholecystectomy. Nowadays, the technique surgical technique of laparoscopic cholecystectomy has become widespread and standardised. In recent years, the organisational model (or care setting) has evolved. which has now mostly changed from ordinary hospitalisation to one-day surgery with discharge within 24 hours of the procedure. The delay discharge on the first postoperative day of patients undergoing patients undergoing VLC, however, remains an obstacle to the improving the quality of care in this surgical procedure. surgical procedure. This study aims to identify the clinical, organisational and social factors that may lead to a delay in the a delay in the discharge of patients undergoing planned VLC This study aims to identify the clinical, organisational and social factors that may lead to a delay in the
dct:language lexvo:eng;
fdp:metadataIssued "2020-07-21T00:00:00Z"^^xsd:date;
dct:issued "2020-07-21T00:00:00Z"^^xsd:date;
dct:modified "2020-07-21T00:00:00Z"^^xsd:date;
fdp:metadataModified "2020-07-21T00:00:00Z"^^xsd:date;
dcat:distribution <http://purl.org/srbr/distribution/dedilaco>;
dcat:theme <http://purl.bioontology.org/ontology/ICD10/K80>;
sio:SIO_000008 [ a ncit:C101302;
ncit:code mesh:D008107, mesh:D002780
], [ a ncit:C70713;
ncit:code loinc:MTHU001009, loinc:MTHU001095, loinc:MTHU002157, loinc:MTHU049889
];
sio:SIO_000061 [ a org:Organization, ncit:C21541;
org:identifier "SA_HEARTH_SURG";
skos:prefLabel "Deparment of General Surgery";
org:subOrganizationOf _:fdp_Organization_SA_HEART;
sio:SIO_000310 _:fdp_Organization_SA_HEART
];
srb:rareDiseases false;
srb:pediatricPopulation false;
dct:creator "PERS19";
srb:collectedDataType obo:OBI_0000671, obo:OMIABIS_0001026, obo:OMIABIS_0001012, obo:OMIABIS_0000060;
srb:cohortDimension "300"^^xsd:int;
srb:studyStatus ocre:OCRE400000;
fdp:metadataIdentifier [ a datacite:Identifier;
dct:identifier <http://purl.org/srbr/fdp/dataset/foobar>
] .
_:fdp_Organization_SA_HEART a org:Organization, ncit:C16696;
org:identifier "SA_HEART";
skos:prefLabel "Sacred Heart" .
```


Conclusioni e sviluppi futuri

Stato attuale: registro popolato con i metadati dei primi 18 studi facenti parte del programma IFAIR

Il modello semantico verrà via via arricchito con nuovi metadati, anche specifici di ogni singolo studio (es. tipologie di esami clinici/procedure presenti nei dataset di ogni singolo studio)

Stiamo costruendo una procedura per la valutazione del grado di FAIRness del Registro, sulla base di algoritmi allo stato dell'arte

Il Semantic Metadata Model e l'applicazione web del Registro verranno pubblicati in Open Source



Grazie per
l'attenzione!

Alessandro Sulis
alessandro.sulis@crs4.it

Acknowledgements: Questo lavoro è stato parzialmente supportato dalla Regione Sardegna, dallo European Joint Programme on Rare Disease (grant agreement N. 825575) e da Sardegna Ricerche all'interno del “Programma I FAIR” (FESR 2014/2020), che coinvolge Sardegna Ricerche, l'Università degli Studi di Cagliari e l'Università degli Studi di Sassari